Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIARA: Iadademstat, Atezolizumab, and SBRT in ES-SCLC
NCT07113691Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Jan 2026
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iadademstat in small cell lung cancer (SCLC), sponsored by Yale University. Primary endpoints: Frequency of Dose-Limiting Toxicities at 35 days, Rate of Dose-Limiting Toxicities at 35 days and 4 more. Started Jan 2026; status: recruiting.
02
Drugs
iadademstat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07113691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07113691.